Correlation of proliferative index with various clinicopathologic prognostic parameters in breast carcinoma
Keywords:
proliferative index, breast carcinoma, Ki-67Abstract
Introduction: Breast cancer (BC) is the most common cancer and the second most common cause of death in women. Prognostic factors are essential in BC diagnosis as they allow the identification of high-risk patients, for whom, an adjuvant therapy can improve prognosis. Interest in Ki-67 has recently increased as Ki-67 is a potential marker for predicting the responsiveness to chemotherapy. Materials and Methods: The study was conducted on 75 consecutive cases of primary breast carcinoma undergoing radical or modified radical mastectomy specimen. Histopathological diagnosis was established on routine hematoxylin and eosin stain and various histologic prognostic parameters including histologic type, histologic grade, and lymph node metastases were assessed. All biopsy proven carcinoma breast were included in this study. Results: Among presenting compliant, 47 (62.66%) had lump in right breast and 28 (37.33%) had lump in left breast. Most patients in the study population presented with a lump of duration 3-6 months (54.6%). Out of 75 participants, 41 (62.66%) participants were diagnosed with carcinoma right beast and 28 (37.33%) with carcinoma left breast. On staging the disease among the study population, most of them diagnosed with breast cancer were of stage IIIB (48%) followed by IIA (25.33%).
Downloads
References
Ahmadi AS, Mahdipour L, Payandeh M, Sadeghi M. Epidemiology, pathology and histochemistry features in women with breast cancer. Am J Cancer Prev. 2015;3:54–7.
Ahmadi AS, Mahdipour L, Payandeh M, Sadeghi M. Epidemiology, pathology and histochemistry features in women with breast cancer. Am J Cancer Prev 2015;3:54-7. 2. Kobayashi T, Iwaya K, Moriya T, Yamasaki T, Tsuda H, Yamamoto J, et al. A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol 2013;13:5.
Albarracin C, Dhamne S. Evolving role of Ki67 as a predictive and prognostic marker in breast cancer. J Clin Exp Pathol. 2014;4:e117.
Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, et al. Ki67 immunostaining in primary breast cancer: Pathological and clinical associations. Br J Cancer 1989;59:943-7.
Cho U, Kim HE, Oh WJ, Yeo MK, Song BJ, Lee A. The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value. Appl Immunohistochem Mol Morphol 2015 Mar 16.
Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol 2005;16:1723-39.
Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013;20:87–93.
Engstrom MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. 2013;140:463–73.
Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486.
Foda AA. No-cost manual method for preparation of tissue microarrays having high quality comparable to semiautomated methods. Appl Immunohistochem Mol Morphol. 2013;21:271–4.
González-Sistal A, Sánchez AB, Del Rio MC, Arias JI, Herranz M, Ruibal A. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program. Anticancer Res 2014;34:269-73.
Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, et al. Ki67 index in breast cancer: Correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev 2013;14:4353-8.
Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139:539–52.
Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013;139:539-52.
Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, et al. Correlation between Ki67 and breast cancer prognosis. Oncology 2013;84:219-25.
Lellé RJ, Heidenreich W, Stauch G, Gerdes J. The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma. Cancer 1987;59:83-8.
Li FY, Wu SG, Zhou J, Sun JY, Lin Q, Lin HX, et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: A retrospective cohort study. PLoS One 2014;9:e87264
Masuda H, Masuda N, Kodama Y, Ogawa M, Karita M, Yamamura J, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol 2011;67:911-7.
Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, et al. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol 2014;2:1062-8.
Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010;1:747-54.
Payandeh M, Malayeri R, Sadeghi M, Sadeghi E, Gholami F. Expression of p53 and Ki67 in the patients with triple negative breast cancer and invasive ductal carcinoma. Am J Cancer Prev 2015;3:58-61.
Payandeh M, Sadeghi M, Sadeghi E, Aeinfar M. Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev 2015;16:4863-7.
Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153:477–91.
Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E, Indelli M, et al. MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol 1996;49:926-30.
Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, et al. Androgen receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PLoS One. 2015;10:e0128368.
Saha Roy S., Vadlamudi R.K.. Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer. 2012; 2012 : 654698 .
Shebl AM, Zalata KR, Amin MM, El-Hawary AK. An inexpensive method of small paraffin tissue microarrays using mechanical pencil tips. Diagn Pathol. 2011;6:117.
Stathopoulos GP, Malamos NA, Markopoulos C, Polychronis A, Armakolas A, Rigatos S, et al. The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anticancer Drugs 2014;25:950-7.
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
Zhang R, Chen HJ, Wei B, Zhang HY, Pang ZG, Zhu H, et al. Reproducibility of the Nottingham modification of the Scarff-Bloom-Richardson histological grading system and the complementary value of Ki-67 to this system. Chin Med J (Engl) 2010;123:1976-82.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
